Table 1 Comparison of demographic and clinical characteristics of the patients with psoriatic arthritis and controls
Patients (n = 50) | Controls (n = 40) | p | |
|---|---|---|---|
Characteristics | Median (minimum-maximum) | Median (minimum-maximum) | |
Age | 47 (23–64) | 45 (25–67) | 0.480 |
Years of education (years) | 5 (0–16) | 11 (0–15) | 0.057 |
MAF score (0–50) | 17.6 (1–43.5) | 1 (1–42.9) | 0.001* |
Psoriasis duration (years) | 16 (1–50) | – | – |
Arthritis duration (years) | 6.5 (1–30) | – | – |
ESR (mm/h) | 13 (2–97) | – | – |
CRP (mg/l) | 0.7 (0.1–18.2) | – | – |
DAS-28 | 2.9 (1.2–5.2) | – | – |
VAS pain score (0–10) | 4.5 (0–9) | – | – |
LEI score (0–6) | 0 (0–3) | – | – |
n (%) | n (%) | ||
Presence of FM | 17 (34) | 4 (11.8) | 0.023* |
Gender | |||
female | 36 (72) | 21 (61.8) | 0.350 |
male | 14 (28) | 13 (38.2) | |
Smoking | 15 (30) | 7 (20.6) | 0.450 |
Occupation | |||
housewife | 28 (56) | 10 (29.4) | 0.024* |
office worker | 11 (22) | 19 (55.9) | |
retired | 11 (22) | 5 (14.7) | |
Medication use | |||
Biological agents | 50 (100) | – | – |
DMARDs | 39 (78) | ||
Corticosteroid | 8 (16) | ||
NSAIDs | 13 (26) | ||